Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women

J Clin Psychopharmacol. 2004 Jun;24(3):339-42. doi: 10.1097/01.jcp.0000125686.20338.c1.


Premenopausal women meeting operational criteria for idiopathic, acquired, global hypoactive sexual desire disorder were studied in a randomized, double-blind, placebo-controlled, multiple-site escalating dose 112-day trial of bupropion sustained release. Outcome was measured by investigator-rating and self-administered questionnaires. All measures indicated greater sexual responsiveness in women receiving bupropion. The Changes in Sexual Functioning Questionnaire indicated that bupropion had significant effects on increasing measures of sexual arousal, orgasm completion, and sexual satisfaction.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bupropion / administration & dosage*
  • Delayed-Action Preparations / administration & dosage
  • Double-Blind Method
  • Female
  • Humans
  • Premenopause / drug effects*
  • Premenopause / physiology
  • Premenopause / psychology
  • Sexual Dysfunctions, Psychological / drug therapy*
  • Sexual Dysfunctions, Psychological / physiopathology
  • Sexual Dysfunctions, Psychological / psychology


  • Delayed-Action Preparations
  • Bupropion